Candel Therapeutics Inc. (CADL) has been drawing attention in the biotechnology space as its share price shows renewed momentum alongside significant clinical and corporate developments. The company's focus on multimodal biological immunotherapies, designed to harness the body's immune system against cancer, has positioned it at the forefront of innovation in oncology.
With late-stage data in prostate cancer, advancing programs in lung cancer, and encouraging survival signals in Glioblastoma, Candel is moving steadily toward pivotal milestones. Recent financing agreements and regulatory designations further strengthen its outlook, making the stock one to watch as it continues to gain traction in the market.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.